CTIS2023-506114-49-00进行中（未招募）1 期
A study of the safety of the new investigational drug CVN293 in healthy volunteers, and how CVN293 is taken up and processed by the human body.
Cerevance Inc.0 个研究点目标入组 64 人开始时间: 2023年7月3日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
To evaluate the efficacy and safety of the newly developed low-intensity ultrasound-transcutaneous nerve stimulation combined therapy for knee pain with osteoarthritis for 20 minutes, 3 times a day (more than 10 times a week) for a total of 8 weeks Single-institution, double-blind, randomized, parallel design, study-based clinical trialsKCT0003883Chonbuk National University Hospital40
已完成
不适用
To evaluate the safety of investigational product by repeat use test for 14 daysCTRI/2019/07/020044ITC Life Sciences Technology Centre40
已完成
不适用
A pilot study of a novel Sternal Protection Device to evaluate its safety in 12 patients requiring a cardiothoracic surgeryACTRN12616000091404Protego Medical Pty Ltd12
已完成
不适用
Investigation about safety and utility of the new minimally invasive needle .JPRN-UMIN000013005Yokohama City University Hospital4
已完成
1 期
A first-in-human study to evaluate the safety tolerability and performance of A/California/7/2009 (H1N1)- like vaccine coated Nanopatches in comparison to placebo coated Nanopatches and intramuscular injection of A/California/7/2009 (H1N1)-like vaccine.. Nanopatches will be delivered to skin using the Vaxxas Clinical Applicator Disposable Device (CAPD).Prophylaxis for H1N1 infectionInfection - Other infectious diseasesACTRN12616000880448Vaxxas Pty Ltd60